期刊
CANCER TREATMENT REVIEWS
卷 40, 期 4, 页码 523-532出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2013.11.006
关键词
Osteosarcoma; Systemic treatment; Outcome; Prognostic factors; Metastatic disease; Mifamurtide; Interferon alpha
类别
资金
- Takeda GmbH
Long-term outcome for patients with high-grade osteosarcoma has improved with the addition of systemic chemotherapy, but subsequent progress has been less marked. Modern, multiagent, dose-intensive chemotherapy in conjunction with surgery achieves a 5-year event-free survival of 60-70% in extremity localized, non-metastatic disease. A major, as yet unsolved, problem is the poor prognosis for metastatic relapse or recurrence, and for patients with axial disease. This article reviews the current state of the art of systemic osteosarcoma therapy by focusing on the experiences of cooperative osteosarcoma groups. Also, we shed light on questions and challenges posed by the aggressiveness of the tumor, and we consider potential future directions that may be critical to progress in the prognosis of high-grade osteosarcoma. (C) 2014 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据